Lone H. Ottesen

2.3k citations

56 papers · 1.4k indexed · 1 hit paper · h-index 18

Pulmonary and Respiratory Medicine top 5%
Molecular Biology
Oncology top 5%
Hepatology top 5%
Cancer Research top 10%

Co-authors: Anders Mellemgaard Remy B. Verheijen Lecia V. Sequist Helena A. Yu Byoung Chul Cho Nasser K. Altorki Wu‐Chou Su Geoffrey R. Oxnard
Topics: Lung Cancer Treatments and Mutations (14 papers)PI3K/AKT/mTOR signaling in cancer (8 papers)Pancreatic and Hepatic Oncology Research (8 papers)
Cited by: Hepatology Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology Blood Hepatology
Partner nations: United States United Kingdom South Korea

In The Last Decade

Lone H. Ottesen

55 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Remy B. Verheijen, Anders Mellemgaard et al. profile →

Peers

Countries citing papers authored by Lone H. Ottesen

Since Specialization

Citations

This map shows the geographic impact of Lone H. Ottesen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lone H. Ottesen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lone H. Ottesen more than expected).

Fields of papers citing papers by Lone H. Ottesen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lone H. Ottesen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lone H. Ottesen. The network helps show where Lone H. Ottesen may publish in the future.

Co-authorship network of co-authors of Lone H. Ottesen

This figure shows the co-authorship network connecting the top 25 collaborators of Lone H. Ottesen. A scholar is included among the top collaborators of Lone H. Ottesen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lone H. Ottesen. Lone H. Ottesen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial 2024 ·Targeted Oncology ·Erika Hamilton,Gerald S. Falchook,Judy S. Wang,Siqing Fu,Amit M. Oza,(unknown),Sanjeev Kumar,Lone H. Ottesen,Ganesh Mugundu,Elza C. de Bruin,Mark J. O’Connor,Suzanne F. Jones,David R. Spigel,Bob T. Li	3
2	Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors 2023 ·Future Oncology ·Paul‐Michael Agapow,(unknown),(unknown),Lone H. Ottesen,Didier Meulendijks	2
3	Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors 2023 ·Cancer Chemotherapy and Pharmacology ·Mats Någård,Mei-Lin Ah-See,James Strauss,Trisha M. Wise‐Draper,Howard Safran,(unknown),William J. Edenfield,Lionel D. Lewis,Lone H. Ottesen,Yan Li,Ganesh Mugundu	1
4	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data 2022 ·European Journal of Cancer ·Laurence Albigès,Daniel Y.C. Heng,Jae‐Lyun Lee,Stephen Walker,Anders Mellemgaard,Lone H. Ottesen,Melanie M. Frigault,Anne L’Hernault,(unknown),Toni K. Choueiri,Mathilde Cancel,Sabina Signoretti	7
5	Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors 2020 ·Cancer Chemotherapy and Pharmacology ·Mats Någård,Mei-Lin Ah-See,Karen So,(unknown),Fiona Thistlethwaite,Mariëtte Labots,Patricia Roxburgh,Alain Ravaud,Mario Campone,Liselot Valkenburg‐van Iersel,Lone H. Ottesen,(unknown),Ganesh Mugundu	8
6	A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases 2020 ·Pharmaceutical Medicine ·(unknown),(unknown),Lone H. Ottesen,Remy B. Verheijen,Dana Ghiorghiu,(unknown)	1
7	Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial 2017 ·Annals of Oncology ·Toni K. Choueiri,Regina I. Jakacki,Dana Ghiorghiu,Vincent Haddad,Alexander Kohlmann,Melanie M. Frigault,Lone H. Ottesen	6
8	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma 2016 ·Clinical Cancer Research ·Thomas Yau,Riccardo Lencioni,Wattana Sukeepaisarnjaroen,Yee Chao,Chia-Jui Yen,(unknown),Pei‐Jer Chen,(unknown),(unknown),Donna S. Cox,Robert Gagnon,Yuan Liu,(unknown),Diptee Kulkarni,Howard Kallender,Lone H. Ottesen,Ronnie T.P. Poon,Donald P. Bottaro	58
9	A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors 2016 ·Investigational New Drugs ·Bojana Milojkovic Kerklaan,S. Slater,Michael Flynn,Alastair Greystoke,Petronella O. Witteveen,(unknown),Filip De Vos,Emma Dean,Larisa Reyderman,Lone H. Ottesen,Malcolm Ranson,Martijn P. Lolkema,Ruth Plummer,Rebecca Kristeleit,T.R. Jeffry Evans,J. Schellens	21
10	A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors 2014 ·Molecular Cancer Therapeutics ·Kari Kendra,Ruth Plummer,Ravi Salgia,Mary O’Brien,Elaine Paul,(unknown),Natalie Compton,Chun‐Fang Xu,Lone H. Ottesen,Miguel A. Villalona‐Calero	28
11	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Giorgio V. Scagliotti,Enriqueta Felip,Benjamin Besse,Joachim von Pawel,Anders Mellemgaard,Martin Reck,Lionel Bosquée,C. Chouaïd,(unknown),Elaine Paul,Rodrigo Ruiz-Soto,(unknown),Lone H. Ottesen,T. Lechevalier	34
12	Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib 2012 ·Investigational New Drugs ·Grace K. Dy,Jeffrey R. Infante,Sabine Eckhardt,Silvia Novello,Wen Wee,Suzanne F. Jones,(unknown),Qiong Wang,A. Benjamin Suttle,Lone H. Ottesen,Alex A. Adjei,Howard A. Burris	4
13	Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors 2012 ·BMC Cancer ·Connie L. Erickson‐Miller,Kodandaram Pillarisetti,(unknown),David J. Figueroa,Lone H. Ottesen,Anne‐Marie Martin,Yuan Liu,Yasser Mostafa Kamel,Conrad A. Messam	15
14	Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII 2005 ·British Journal of Cancer ·Mikkel W. Pedersen,Nina Marie Pedersen,Lone H. Ottesen,Hans Skovgaard Poulsen	69
15	Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis 2002 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Lone H. Ottesen,Jan Frystyk,Marianne Kiszka‐Kanowitz,Henning Grønbæk,Flemming Bendtsen,Allan Flyvbjerg	3
16	Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial 2001 ·Hepatology ·Lone H. Ottesen,Niels Kristian Aagaard,Marianne Kiszka‐Kanowitz,Michael Rehling,Jens H. Henriksen,(unknown),Allan Flyvbjerg,Flemming Bendtsen	24
17	Increased formation of S-nitrothiols and nitrotyrosine in cirrhotic rats during endotoxemia 2001 ·Free Radical Biology and Medicine ·Lone H. Ottesen,David Harry,Matthew Frost,Nathan Davies,Korsa Khan,Barry Halliwell,Kevin Moore	65
18	The insulin‐like growth factor binding protein 3 ternary complex is reduced in cirrhosis 2001 ·Liver International ·Lone H. Ottesen,Flemming Bendtsen,Allan Flyvbjerg	10
19	Protein C Activation during the Initial Phase of Experimental Acute Pancreatitis in the Rabbit 1999 ·Digestive Surgery ·Lone H. Ottesen,Else‐Marie Bladbjerg,Maher Osman,(unknown),N Jacobsen,Jørgen Gram,S L Jensen	28
20	The pharmacokinetics of octreotide in cirrhosis and in healthy man 1997 ·Journal of Hepatology ·Lone H. Ottesen,Allan Flyvbjerg,Preben Jakobsen,Flemming Bendtsen	26

About Lone H. Ottesen

Lone H. Ottesen is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine, having authored 56 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (14 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Pancreatic and Hepatic Oncology Research (8 papers). The work is most often cited by research in Hepatology (237 citations), Oncology (618 citations) and Pulmonary and Respiratory Medicine (698 citations). Lone H. Ottesen has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include Anders Mellemgaard, Remy B. Verheijen, Lecia V. Sequist, Helena A. Yu, Byoung Chul Cho, Nasser K. Altorki, Wu‐Chou Su, Geoffrey R. Oxnard, James Chih‐Hsin Yang and Sergey Orlov. Their work appears in journals such as Journal of Clinical Oncology, Blood and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact